Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API

Siponimod API  - Dr. Reddy’s

Siponimod is an oral, second-generation sphingosine-1-phosphate (S1P) receptor modulator. S1P receptor modulators can inhibit the egress and recirculation of lymphocytes from lymph nodes, a therapeutic strategy for treating certain autoimmune diseases.

Siponimod is the first and only treatment for patients with active secondary progressive multiple sclerosis (SPMS). The drug is expected to address the critical unmet need of multiple sclerosis patients in various disease categories [1].

Dr. Reddy’s Siponimod API is another example of the technical capabilities of our product development team. We can provide our partners with a Siponimod Hemifumarate API, which is thoroughly characterized by its structure using techniques like MicroED, single crystal PXRD, DSC, Raman, FT-IR, and NMR (solid-state and solution). Siponimod Hemifumarate was confirmed as a co- crystal, and it exists as a 2:1 co-crystal of Siponimod and fumaric acid rather than fumarate salt.

To know more about our API offerings, please read the White Paper on Siponimod by filling the contact from below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

X

Have you booked your
CPHI Japan meeting slot yet?

Join us at booth: 5N-12

17th-19th April 2024

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Schedule a meeting